Sanofi (SNY.US) submits application for new indication of long-acting RSV monoclonal antibody

```htmlAccording to Golden Ten Data, on August 7, the CDE official website announced that Sanofi (SNY.US)'s nirsevimab injection application for a new indication was accepted, with registration classified as Category 3.1. Based on public information and clinical trial progress, the Insight database speculates that the indication applied for this time is the prevention of lower respiratory tract infections caused by respiratory syncytial virus (RSV) in the following infants: newborns and infants who are about to enter or are born during the second RSV infection season.```